Immunoadsorption for Treatment of Patients with Suspected Alzheimer Dementia and Agonistic Autoantibodies against Alpha1a-Adrenoceptor-Rationale and Design of the IMAD Pilot Study.
Sylvia StrackeSandra LangeSarah BornmannHolger KockLara SchulzeJohanna Klinger-KönigSusanne BöhmAntje VogelgesangFelix von PodewilsAgnes FöelStefan GrossKatrin WenzelGerd WallukatHarald PrüssAlexander DresselRudolf KunzeHans J GrabeSoenke LangnerMarcus DörrPublished in: Journal of clinical medicine (2020)
IMAD is an important pilot study that will analyze whether the removal of α1AR-agAABs by immunoadsorption in α1AR-agAAB-positive patients with suspected Alzheimer's clinical syndrome may slow the progression of dementia and/or may improve vascular functional parameters.